advocate for franchisees 154
ageing business owner, business exits 44
agency theory 8, 229–30
age-specific death rates for organizations 30
allergy, intellectual property 77, 79
allergy program of ImmuLogic 75–7
angel investors 223
appointment missing 140
Arkwright’s textile mill, 1771 15
attitude and behavioral intention 172
auto producers, US, decline 22–3
autoimmune research program 63, 77–9
partnership of ImmuLogic and Merck 78–9
automobile industry
Europe 26
French and British, rapid sustained growth 26
US, entry and decline 23–4
autonomy influence against retirement 168–9

Bamburg, Jill
bankruptcy 173
beer brewer decline, US 23
behavior
acceptable, in workplace 147
control 164
disenagement, coping behavior 191

Ben & Jerry’s ice cream company 8
all-natural ingredients 221
’selling out’ 221–2
Unilever acquirement, 2000 215, 235, 240

Benefit Corporation in state law 215, 223
biographical information of individuals in organization 72
biotechnology firms founding by scientific individual from ImmuLogic 83
birth rates lowering 157
Body Shop
more than what it sells 219
sale to L’Oréal, 2006 219–20
bridge employment option
full or part-time after retirement 158
Burt’s Bees, sale to Clorox 215
business and economic theories, alternatives 207
business angels 5, 223
investment in entrepreneurial firms 89
business bankruptcy, exit route 13
business characteristics 107, 135
Business Employment Dynamics Database
measuring business births and deaths 32–3
business exit
and business failure, coterminous 47
from gendered perspective 42–59
business founding rates
increase or decrease reasons 22
business-level consequences of retirement 178
business premises, importance of 250
business tracking from birth 107
business transfer failure
emotional and psychological aspects 184–5
business, ultimate purpose for 155–6
businesses, necessity-driven 204
buyback
entrepreneurial firm buying VC investor’s shares 95
cancer death of business partner 141
Cantab Pharmaceuticals, UK-based 79
capitalist economic systems, business role in 37
capitalist systems 3, 11, 14
captive VCs (CVCs) 102
career histories, sources for
    ImmuLogic scientists, academic
    partners 72
cash acquisition method of payment
    95
cash reserves for exited firm, results of
    exit 231
cat allergies, ImmuLogic 75, 77
CATVAX intellectual property,
    ImmuLogic 77
censoring of an observation 112
certification hypothesis 101
Chappell, Tom (Tom’s of Maine)
    The Soul of a Business 218
children as successors, choice
    jealousy and rivalry 187
Chouinard, Yvon
    founder of Patagonia 218
    Let my People Go Surfing (2005) 218
coal-mining industries 16
cocaine addiction vaccine 82
    Celtic Pharmaceutical 80
Cohen, Ben (Ben & Jerry’s) 221
commercial-based loans
    commercial entrepreneurs 233
commitment
    empty love 205–6
    relationship forming 204
common equity securities, weaker
    control rights 98
communication, long-distance
    postal and telegraph service 16
communication studies 37
community trade, Body Shop 219
company patents, reinvestment of 65
compassion in social entrepreneurship
    232
competency embeddedness 68
competing risk analysis 111–12, 122–3
competition, always to be aware of
    148–50
control mechanism of VC investors
    staging investments 92
controlling interest, ability to keep
    238
convertible preferred equity
    strong control rights 98
COPE tool 191
coping
    adaptive, emotion-based, problem-
    based 190–91
    strategy effectiveness, assess by
    results 193
    stress regulation 189–90
    corporate buyers 242
corporation for company stores 131
costs and benefits of solutions
    problem-based coping 190
Cox competing risks: time varying
    covariates 119–20
Cox proportional hazard regression
    model 117
craftsmen, unemployed 16
Cranet Survey 249
creativity and passion 203
credit unions, state-charted, decline
    22
cross-sectional surveys and weights
    108–9
data assessment 193
death/harvest/exit debate, gender blind
    48
debt, unsecured 155
decision sharing
    positives and negatives of young
    worker 131
delgation of authority, importance of
    145–6
denial, coping behavior 191
diabetes treatments 78
digital information 17
    late 20th century 15
direct mail campaigns 133–4
discovery, evaluation, exploitation of
    opportunities 216
discrete time models, time-varying
    covariates 127
disengagement, entrepreneurial
    197–200
distrust of successor
    psychological barriers to exits 187–8
dog projects, ImmuLogic 75
domestic labour and child care
    women’s responsibility 50
donomination structures 220–22
    power over resources 216–17
Dow Chemical, 75
duration analysis 112
duration models 124
economic advantage of franchising 133
economic-forced exits
   higher for male managers 44
economic rationality 199
education, continued after retirement 158
efficiency and effectiveness
   valuable for social firm 235–6
electrical engineering 16
emotional aspects 9
   of entrepreneurial exit 7–8
   grief, guilt, depression, despair, anger, frustration, loss 191
emotional attachment as psychological barrier 186
emotional connections with business 200
emotional social support, coping behavior 191
emotions before retirement, fear, anxiety, uselessness 177
emotions, in entrepreneurial processes 199, 207
employees of business
   care for, in exit strategy 156
employer business population, US births and deaths 1993–2010 34
   volatility in 33
entrepreneur experience
   effect on exit intentions 102
entrepreneur perspective, beginning and exit 128–56
entrepreneurial activities of women, limitations
   gendered ascriptions at fault 50–51
entrepreneurial break-up 197–210
entrepreneurial career endings
   avoidance or incentives to retire 177
entrepreneurial context retirement intentions
   identity, psychological ownership, dependence of venture 167
entrepreneurial control over retirement 162–3
entrepreneurial disengagement 200
entrepreneurial exit 1–2, 11–38
   conference, Sweden 2013 2
decisions in gender-aware scenarios 56
firms and individuals 12
highest, following start-up 28
importance of understanding 214
literature 199, 241
not always negative 69
path-dependent process 173
push and pull factors 175–6
specific cases 91
entrepreneurial experience
   high exit effort, greater 172
   learning by doing 171
entrepreneurial firm monitoring by VC investors 92
entrepreneurial identity 7
   attributes, content, role regard, centrality 167
negative relationship with retirement intention 167–8
entrepreneurial learning, major role in venture founding 35
entrepreneurial life cycle 67–70
‘entrepreneurial recycling’ 65
   benefit at ImmuLogic 83
entrepreneurs and venture survival 169
entrepreneurs’ choice in location 249
entrepreneurship, coping strategies 189–91
entrepreneurship research 6
entrepreneurs’ retirement intention
   macrolevel factors 178
entrepreneurs, start-ups, criteria for qualification 31
environment, adaptation to 35
environment and animal protection, Body Shop 219
equity firms, investments in social ventures 233
equity ownership loss
   possibility of staying with company 156
European Private Equity and Venture Capital Association (EVCA) 90
European Union
   continued ageing of business owners, 2012 185
European Venture Capital Association (EVCA) 96
event history analysis (EHA) methods 114–23
survival, duration, failure time, hazard 111–14
events of interest 122, 124
exit behaviour relationship 8
exit determinants 96–9
exit effort
higher, exit strategies, more value 174
importance of 176
methods need 169–174
sample activities 170
exit motives for entrepreneurs and investors 97
exit options for social ventures 214
exit outcomes 99–102
‘exit’ plan from beginning 155
exit prospects of capitalist nations 27
exit research
individual level 256
relevance 255–8
exit route, choice of 97–9
exit stage 93–4
exit strategy
differences
protection for those involved 156
VC investors and entrepreneur 97
when to begin 156
exit timing 96–7
exit vehicles, principal
IPO, acquisition, secondary sale, buy back, write-off 94
exit via partners, venture capitalists, angel investors, IPOs 239
exiting for economic reasons, ‘selling out’ 219
exits and failures 13–14
exits due to retirement, implications of 178
exits from poor or strong performance 226
exits, good or bad 42
exits, low-key 56
exits not failures 14
expansion method 131
experimental designs use research into psychological barriers 193
export out of region 253
factory production
textile and machinery industries 15
failure rates 99
family and non-family transfers, samples 193
family business context
psychological barriers to exits 187
family farming, non-violence causes, Ben & Jerry’s 221
family ownership 31
family succession 173
farms, exits to cities 16
FASTSIGNS International, Inc. 6, 130–32, 134
competition with Kinko 149
continuous growth 143–4
exit, insights from 155–6
franchise launch, 1986 134
potential merger with Kinko 148
regret at selling 154
research questions on ‘exit’ 156
trading cash for control 153
fear of mortality
in increasing age of entrepreneurs 188
psychological barriers to exits 187
female entrepreneurship, as gender bias 50
femininity of firm owners
constrained performance of business 53
finance problems for women 44
financial and production capital profit pursuing 14
financial earnings standpoint measurements for objectives 132
financial gain, exit for, ‘selling out’ 214
financial incentives for firm location 248
firm entry and exit rate, growth in productivity 255
firm exiting, Kauffman Firm Survey 111
firm interdependencies 253
firm-level research 256–7
firm migration determinants firm or site-related factors 250
firm relocation 9
at regional level 255
findings 249–50
from region to region 246–7
size of premises factor 258
fitness, declining, retirement intention 166
Food and Drug Administration (FDA) 75, 82
formal and informal retirement preparation 167
formal connections between organizations 68
founders, exits of 13
founder’s intimacy 202–3
founder’s wealth of firm, reinvestment of 65
franchise corporate entity, setting up 133–4
franchise opportunity 133–5
franchisee qualifications and suitability 134–5
franchisees, concern for, competition with Kinko 149
franchisees, needful characteristics 135
franchising the concept, to avoid debt 133
franchisor system preparation operations manuals, marketing strategies 134
future research directions, empirical investigation 242–3
gendered influences during entrepreneurial process 46
gender, effect on business closure 4, 9, 43, 57
general or descriptive trade names, avoidance 136
General Partners (GPs), for venture capitalists 88
global economic disparities developed and developing countries 214
Global Entrepreneurship Monitor 2012
women in sub-Saharan Africa, business closures 43
global exchange networks, Europe and North America 16
goals, higher, good for exit effort 171
governance and personnel decisions 132
grass project, ImmuLogic 75
Greenfield, Jerry (Ben and Jerry’s) 221
hazard rate, risk of exit for firm 115
health care, rising costs 157
health maintenance organization (HMO), USA 19
heavy engineering, late 19th century 15
Heska Corporation, and ImmuLogic 77
high-status careers of women 58
high-technology businesses, KFS oversampling 108
hiring of young graduate for new business 131
historical eras, coverage 9, 27
HLA blocker, ImmuLogic product 78
home-based businesses of women 51
less profitability than men 55
home location choice 248–51
horse-drawn transportation 16, 22
house dust mite
Circassia research area 77
clinical trials, ImmuLogic 73
human behaviour and emotions 199
human capital 170
education, age, experience 187
endowment, enhanced, higher exit effort 171
human love, types of 201
human resource benefits 107
human rights, Body Shop 219
‘human rights and environmental issues’ 219
identity link to venture, personal characteristics 167
identity loss, fear of psychological barriers to exits 188
immigration from Europe urban workforce increase 16–17
ImmuLogic, 1987
biotechnology firm, Boston USA 70
closure, liquidation of assets 63
Malcolm L. Gefter, tenured professor 63–84
number of articles written 73  
onofficial transfers of knowledge 74  
partner with Merck  
in discovery research, less success 81  
partner with MMD  
on allergy program, success of 81  
program duration, funding sources 74  
record of patents 70–71, 75  
research projects termination 63  
strategic alliance with Merck 73–4  
immunology, treatment for common  
allergies 63  
immunotherapy tablets, for allergies 77  
impartial third party  
importance of between business  
partners 144  
independent VC investors 102  
preference for immediate exit routes 97  
individual retirement, and  
entrepreneurial exit 6–7  
individual women, behaviour like men,  
to succeed 45  
individuals as units of analysis 13  
individual-to-individual ties 66  
individual-to-organization, two-mode  
networks 65–6  
industrial development, mechanized  
production 3  
Industrial Revolution 3, 15–17  
18th and 19th century 15  
industry and population level 18–27  
industry experience, age, education  
effect on exit intentions 102  
inertia, structural 257  
information asymmetries 94  
risk of adverse selection 88  
risk of moral hazard 88  
infrastucture building 145  
initial founding conditions, imprint  
of 35  
initial public offerings (IPO) 59  
American markets 66  
exports 94, 96–8  
sale of firm shares on public market 94  
VC role 100, 102  
inkjet technology 148–9  
inovation and capitalist growth 11  
inovations, diffusion of 3  
inovative ventures, IPO exits more  
common 98  
inallectual property, portfolio of  
patents 81  
inallectual property protection 6, 132,  
135–7  
intent, for retirement  
behavioral control 164  
good reasons to 163  
inereests outside firm  
positive relationship with transfer 187  
nternal combustion engine 3  
nternational trademarking 136  
nternet-based sales and distribution 17  
intimacy  
basis for friendship 205–6  
nascent venture-nascent  
tepreneur relationship 202  
intimacy, passion, commitment  
consummate love, disengagement 206  
vestment selection 91–2  
vestors (fund providers) 5  
iron and coal-mining 16  
 Japanese cedar project, ImmuLogic 75  
alousy and rivalry, between siblings 188  
favouritism 187  
Jordan, Kim  
CEO of New Belgium Brewing Inc.  
New Belgium core values 220  
Journal of Business Venturing 1  
Kaplan–Meier  
product-limit method 114–15  
kauffman Firm Survey (KFS)  
inesses assigned longitudinal  
weight 111  
data set 6  
longitudinal study 107, 124  
of new businesses 107–24  
panel data 110  
single-cohort panel 107
target population, sample design 108
keep (stay) factors acting as sunk costs 253
employee retention 253
unwillingness to relocate 257
knowledge codification, after partnership 81
localized 253
spillover effects of firms in region 255
knowledge-based sectors of economy 36
labour market areas (LMA), US 247–8
labour market positioning for women 48–9
lease negotiation 129, 131
legacy creation philanthropic and pro-social behaviors 172
legacy leaving in entrepreneurial exit 172
retirement intention strong 172
legal protection 132
legal ramifications of partnerships 141–5
insights from 144
legitimation structures 219–20
values for dispensing rewards 216–17
LexisNexis database for newspaper and other articles 72
life-cycle perspective 83, 150, 157, 254
life tables, construction 115
life tables example 117
Limited Partners (LPs) for investors 88
loans, short and long-term commercial entrepreneur 233
logit response models, multinomial approach to competing risks 122
L’Oréal cosmetic group, no testing on animals 220
love, triangular theory of 206–7
intimacy, passion and decision, commitment 199
strong feelings for ventures 199
love, types of, and evolution of 208
loving relationship between founders and their ventures 200–202
low cash reserves, threat to social venture 233–4
managerial and human resource issues 37
managerial control, for firm’s social goals 239–40
managerial roles, results of exit 231
managing relationships, insights from 139
Marine Hospital Service, USA, prepaid medical care 19
mass production in manufacturing automobiles, home appliances 16
Massachusetts Institute of Technology (MIT) 63
maternal health issues in developing countries 215
maternal responsibilities, not all women 58
mechanization, textile and machinery industries 15
medium-technology businesses KFS oversampling 108
MEDLINE database record of authors for ImmuLogic 71–2
meeting with partner’s family and attorney 142–3
mental disengagement, coping behavior 191
mergers and acquisitions (M&A) 1, 96–8, 242
Metropolitan Statistical Areas, US 247
microelectronics 3, Middle East and North Africa (MENA)/Mid-Asia region fewer start-ups from women 43
Millennium Pharmaceuticals 76
mission-driven entrepreneur 214, 219
preservation of original values 223
model of van Teeffelen on transfer, pre and post transfer phases 186
money investment, assumptions 233
money or control 150–53
moral hazard risk 88–9
Morgenstern, contact for allergy program 76
motivation and behaviors of partner 139–40
multi-episode – longitudinal data 113–14
multiple sclerosis, ImmuLogic work on 78–9
name change, SIGNWAVE 136
nascent entrepreneurial disengagement 197–201, 205
National Foundation of Independent Businesses (NFIB) 1
National Institute of Health (NIH) 79 funding for research 71
National Institute on Drug Abuse (NIDA) 79–80
National Venture Capital Association (NVCA) 96
natural capitalism 214–15
natural personal hygiene goods, Tom’s of Maine 218
negation of ‘continuation’ 198
negative cash flow, threat to social venture 233–4
network perspective 65–7, 83
network reconfiguring after exit 69–70
New Belgium Brewing Company 8 partnerships with microbrewing companies 220
wind energy use, water conservation program 220
new ventures, survival or non-survival 29, 197
newness, liability of 30
estimate for PSEDII sample 32
social capital, retirement intentions 31
non-informative (random) censoring 112
nonparametric analysis
Kaplan–Meier and Life Tables 114
normative exit routes 56
offer of 20% ownership after sale of FASTSIGNS 150–51
Office of Extramural Research National Institutes of Health (NIH) 71
patent driven research stream, ImmuLogic funding 75

Panel Study of Entrepreneurial Dynamics (PSED) liability of newness 30–31
parametric analysis of duration data 114, 118–21
parametric proportional hazards (PH) 118
parametric regression, time-varying covariates 125–6
parent-child analogy 81–2
partial buyback
sale of part of VC investor’s holdings 95
partial exit of social entrepreneur retaining majority ownership 238–9
partners and franchises 4
importance of close connection with 150
partner sexual misbehaviour, costs involved 145–6
partnership agreement
partner’s stock bought before death 143
part-time businesses of women 51
passion 205–8
source of motivational arousal 203–4
Patagonia Inc. 218

Dawn R. DeTienne and Karl Wennberg - 9781782546979
Downloaded from Elgar Online at 12/25/2018 02:27:52AM via free access
patent protection of intellectual property 170
patents of ImmuLogic, 64, 73
personal connections
individuals from multiple organizations 65
individual-to-organization connections 66
personal embeddedness 67–8
personal network of entrepreneur 67–8
personal responsibilities in business venture 130
personal variables 176
personnel issues, relocation in US 131–2
philosophy of business
financial security vehicle 156
Point Therapeutics, staff move from ImmuLogic 76
policy initiatives, on firms’ relocation 258
population aging in developed nations research on retirement 158
population decline, excess of exits over entries, 22
‘population density’ 18–20, 258
population growth and decline, 27 in 23 US industries 21
populations, organizational major decline examples in US 23
positive associations with retirement optimal exit strategy 175
women’s position on this 56
positive reinterpretation, coping behavior 191
post-investment monitoring 92–3
postponement risk of business transfer incompetent successor chosen on purpose 185
incumbent refusal to delegate 185
lagging of investment 184
liquidation 184
unavailability of successor 184
post-retirement options 157
prejudice against succession planning psychological barriers to exits 188
price offer assessment, coping behavior 190
primary wage earners, social pressures on men 55
Principal Registration, for trade names, US 136
private equity activity, definition 90
private equity funds, closed-end nature 93
private equity (PE) 151–5
problem definition, problem-based coping 190
product license application (PLA) 75
product market competition 98
projected marginal costs (PMC) 96
projected marginal value added (PMVA) 96
psychological barriers, in business transfers 184–93
coping strategies 192
psychological barriers, known 187–9
psychological barriers to exits 7, 9
connection with types of coping 192–3
detection of 189
further understanding 189
literature on 185–7
psychological ownership, higher lower retirement intention 167–8
psychology 37
pull factors for relocation 257
proximity to customers, or raw materials 252–4
push factors for relocation, lack of growth space 252
quality of exit opposed to harvest amount 242
R&D alliances 66
R&D investment in biotechnology company 66
ragweed allergies, ImmuLogic 75
railway operating decline 22
railways, introduction of 3
railways and steam 15–16
random censoring 112
RBV see resource-based view
recession of 2008 12, 32–3
refinancing fees 153
regional clusters for manufacturing firms 253
regional embeddedness 249
identity link to venture 163
intentions and reasons 162
intention behaviors 170–71
non-work factors 161
positive attitudes towards health, wealth gender (male), and age 166
positive effect on exit effort 171
push or pull factors 161–2
reasons for 159, 165–9
research model 164–5, 174–5
result in exit strategy 175
theoretical perspectives 160
work-related factors 161
return on assets (ROA) 101
return on investment (ROI) 221
rheumatoid arthritis treatments 78
right-censored cases in KFS, patterns of 113
right-censoring of data 31, 112
risk of nascent entrepreneur disengagement 204
Roddick, Anita
*Body and Soul* (1991) 219
’social and environmental change’ 219
The Body Shop, sale to L’Oréal 215
role change and degradation of power psychological barriers to exits 187–8
role regard, positive or negative assessments 167
sale of existing businesses, of both partners 131
sale of FASTSIGNS 152–3
sale or liquidation 173
sales objective, financial 131
scientific advisory board (SAB) members 82
secondary sale of VC investor’s shares 95–6
Security Exchange Commission (SEC) ImmuLogic’s corporate history 71–2
seed stage investors undeveloped technology and concept 89
self-efficacy of entrepreneurs 177
self-regulation of entrepreneurs 177
seller’s perspective of deal, investigation 242
sensitivity counselling for business staff member 145
Shane and Venkataraman, entrepreneurial process 226
shareholder and partnership paperwork agreement upon 130
shareholders’ agreement
life insurance, buyout mechanism 137
partner, prior resistance and difficulties 137–8
reluctance of one partner 131
shoes, sold, pair given to child in need Argentinian-inspired 236
signage, computer generated successful sales 132
signification structures 217–19
meaning in social interactions 216–17
sign makers, hiring of 131–2
single-episode − longitudinal data 113
site selection 129, 139
size of firm, influence on relation 250
social and commercial ventures
four differences 232
social and professional relationships 82–3
social and sustainable ventures 221
social capital, importance in home region 251
social embeddedness, keep factor 253
social entrepreneurs 8, 214, 218, 226
altruistic objectives for exit 232
how they exit social ventures 14–18, 226–43
literature 241
motivations for exit 230–32
reasons for exit 231
resource-based view (RBV) 229
successful exits for 214
theoretical background 229–30
timing of exits 243
social goals pursuing, no guarantee 238
social goals serving exit as conceivable motivation 236
social mission firms 215, 218
social purpose of venture, exit less likely 218, 220
social relationships data, ImmuLogic 80
social responsibility, Body Shop 219
social skills, tenacity, achievement need of entrepreneurs 177–8
social support, coping behavior 191
social values competition with economic values
exit less likely 220
social ventures 214–23
attacking social issues 226
exit examples 8, 227
social vision, need to live on 234
social wealth increase 214
society-level emergence and exit 15
socio-economic context
women’s disadvantaged position 49, 53
socio-economic framework of society inertia 14
’spectacular’ failures, societal stigma, sense of loss 57
staff hiring interviews 140
staff scientists 82
staff training system 147
staged financing 92
stakeholder reactions to retirement 178
stand-alone analysis 108
start-up phase, disengagement from 197
start-up process, commitment importance 204
start-up year, Kauffman Firm Survey 111
state-chartered credit unions decline New York 23
steam and railways, early to mid-19th century 3, 15–16
stock market conditions
crucial for IPO’s VC backed timing 94
stock method of payment 95
store design and opening 129, 131
stores, second and third, opening in other towns in Texas 133
stress, effective dealing
importance in entrepreneurship 190
structuration theory 8
entrepreneurial exit of social ventures 222
interdependence of context (structure) and actor (agent) 216
substance abuse program 79–80
substance use, coping behavior 191
success in start-up teams 130
succession planning, prejudice against tendency not to plan 187
sunk costs 253
Supplemental Registration, for trade names, US 136
support of business owner 139
suppression of competing activities coping behavior 191
survival function, Kaplan–Meier estimate 31
‘survival probability’ definition 29

team relations 130
team start-ups 29, 209
technological change, emergence of new industries 14
technological innovations, late nineteenth century 15–16
telecommunications 3, 17
late 20th century 15
temporal stability 172–3
The Body Shop, structuration theory 8
theory of planned behavior (TPB) 158, 176–7
theory testing 208
time and energy investment, assumptions 232–3
time management 146
time models of duration 121–2
timekeeping, careless 140
timelines for ImmuLogic 73
time-to-event data 111–12
methods for analysing 114
tire industry, US, 1900–1980
entry and exit rates 24–6
Tom’s of Maine. structuration theory 8
non-phosphate laundry detergent sales 218
sale to Colgate/Palmolive 215
‘Tom’s: Shoes for Tomorrow’

for-profit venture. ‘alpargata’ shoes 236–7
toothpaste, all-natural, Tom’s of Maine 218
total entrepreneurial activity (TEA) 43
total factor productivity (TFP) 93
trade associations 36
trade sale of entrepreneurial firm to another company 95
trade sales exits 96
trademarking, insights from attorney in field 136
clear view of costs 136
trademarking of names 134–7
transportation, long-distance handicraft goods, locally produced 16
travel and insurance agencies 17
triple-bottom-line performance
economic, environmental, social success 215
twenty-first century, early genomics and bio-informatics 17
types of analyses, Kaplan–Meier graphs 6
underpricing 100
unemployment insurance tax accounts 32
online database of patents 70
Unilever, consumer products company Ben & Jerry’s right to sue 221
Ben & Jerry’s sold to, by shareholders 221
VRIN resources from Ben & Jerry’s 235
Unilever, protection of current employees 240
United States Patent and Trademark Office (USPTO)
units of analysis 12–14
US railways decline 23
vaccine against cocaine, ImmuLogic 79
vaccines for substance abuse 63
value-adding activities, control mechanism of VC 92
values 219–20
centrality of, for social entrepreneurs 219
variability, evolution and innovation 37
positive association with company performance 101
Venkataraman (1997) resource acquisition and utilization 221
venture capital (VC) active management of entrepreneurial firm 88
exit stage 87–103
financing process 91–6
formal and informal 89
funding 9, 88
investments 5
investor characteristics and exit outcome 99
investor, role at exit stage 100–101
investor types captive VCs (CVCs) 102 independent VCs (IVCs) 102 investor’s role after exit stage 101–2 reputation 99 investment duration comparison of USA and Europe 96–7 investments 88 positive influence on firm employees, sales growth 93 partnership with firm 88 role at exit stage 99–102 seed stage investors 89 venture creation stage, social networks 5 venture dependence on entrepreneur low retirement intention 169 vinyl applications 148–9 voting power of VC investors 92 VRIN resources negative relationship with intention to exit 237 outside of social venture 236–7 outside social firm 234–7 waged employment for women cause of entrepreneurial exit 54 waged employment, good quality more suitable for women 52 waged employment, lower returns women-owned firms 51 Wedgewood pottery 15 weights, provision by KFS longitudinal and cross-sectional 108–11 women and self-employment in UK 43 women as secondary earners 55 women entrepreneurs, fewer ‘spectacular’ failures 57 women seen as limited performers in entrepreneurial projects 50 women-owned businesses alleged ‘problems’ 53 from home or part-time 49 women’s exclusion by child care responsibilities 55 women’s exits less profitability than men 43–4 work as source of self-identity 166 work behavior 107 working definitions of important issues time, agreements, delivery of 140 work-role attachment job involvement, company identification 166 World Wide Web 3 write-off, full implication of bankruptcy of firm 95 write-off, partial 95 young firms, interregional choices 250